As of 4:01pm ET
| -2.55 / -3.01%|
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. It operates through the Human Pharmaceutical Products and Animal Health segments. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular, and other. The Animal health segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The Other Pharmaceuticals products include anti-infectives, primarily Vancocin and Ceclor, and other miscellaneous pharmaceutical products and services. Its products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.
|David A. Ricks||Chairman, President & Chief Executive Officer|
|Derica W. Rice||Chief Financial Officer & EVP-Global Services|
|Jan M. Lundberg||Executive Vice President-Science & Technology|
|Melissa Stapleton Barnes||Chief Ethics & Compliance Officer, Senior VP|
|Jeffrey N. Simmons||Senior Vice President|